U.S. Markets open in 5 hrs 35 mins

Kinnate Biopharma Inc. (KNTE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.53+0.87 (+5.93%)
At close: 04:00PM EST
15.53 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.66
Bid0.00 x 800
Ask0.00 x 1100
Day's Range14.40 - 15.54
52 Week Range14.24 - 41.00
Avg. Volume96,525
Market Cap678.6M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.50
  • GlobeNewswire

    Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones

    Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combination portion with binimetinib planned for first half of 2022 Announces planned initiation of Phase 1 trial of KIN-3248 for first half of 2022 subject to IND clearance by the FDA Updated cash, cash equivalents and investments of approximately $324.9 mill


    Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...

    Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.

  • GlobeNewswire

    Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings

    AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors ASCO GI Cancers Symposium presentation will highlight results from preclinical studies evaluating the company’s lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248 SAN FRANCISCO and SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopha